Can We Detect Alzheimer’s Before Memory Loss Begins?

Most people think Alzheimer’s disease begins with forgetting names, missing dates, or struggling to recognize familiar faces. In reality, these more obvious symptoms often appear years after the disease has already begun changing the brain. During this silent stage, brain cells and the connections between them gradually become damaged, affecting not only memory but also thinking, learning, decision-making, and eventually a person’s ability to carry out everyday activities. By the time memory problems become obvious, many of these changes have already taken place.

This delay in diagnosis is one of the greatest challenges in Alzheimer’s care. Currently, doctors can detect early signs of the disease using brain scans or by analyzing cerebrospinal fluid obtained through a lumbar puncture. While these options offer a way to detect the disease early on, they may be costly, invasive, or not be available in many health care facilities. This makes it possible for a lot of individuals to be diagnosed only when symptoms manifest.

So, what if detecting Alzheimer’s could be as simple as taking a blood sample during a routine clinic visit?

Seeking a more accessible approach to early diagnosis, Salvadó and colleagues investigated whether a blood biomarker called plasma phosphorylated tau 217 (p-tau217) could identify the earliest biological signs of Alzheimer’s disease before memory problems became apparent. Researchers investigated whether a blood protein called plasma p-tau217 could identify the earliest biological signs of Alzheimer’s disease in people who had not yet developed memory problems. If successful, this approach could make early diagnosis more accessible and help identify people who may benefit from emerging treatments or clinical trials sooner. 

Instead of waiting until people developed memory loss, the researchers focused on an earlier stage of Alzheimer’s disease known as the preclinical stage. During this period, individuals appear healthy in everyday life, but harmful changes associated with Alzheimer’s have already begun inside the brain.

To investigate whether a blood test could detect these hidden changes, the researchers collected blood samples from participants and measured the amount of plasma p-tau217, a protein that increases as Alzheimer ‘s-related changes develop. They then compared these blood test results with established methods of detecting Alzheimer’s pathology, including brain imaging and cerebrospinal fluid analysis. This allowed them to determine how accurately the blood test reflected what was happening inside the brain. 

The results were encouraging. Higher levels of plasma p-tau217 closely matched the presence of Alzheimer ‘s-related brain changes, even in people who had no noticeable symptoms. The researchers also found that using carefully selected decision thresholds could reduce the number of people needing more invasive or expensive confirmatory tests while maintaining strong diagnostic accuracy. Rather than replacing existing diagnostic methods, the blood test could serve as an effective first step in identifying people who should receive additional evaluation. 

What makes this study particularly exciting is not that it makes early detection possible, but that it could make early detection simpler, less invasive, and more accessible through a blood test. It changes what is currently possible.

When the disease is recognized before memory loss begins, people may have more opportunities to participate in clinical trials, consider emerging treatments, plan for the future, and receive care at a stage when interventions are more likely to have meaningful benefits. Earlier diagnosis also helps researchers better understand how Alzheimer’s develops and evaluate new therapies before extensive brain damage has occurred.

While additional research is required for a blood test to be part of a standard medical check-up, this study is a significant step toward making the diagnosis of Alzheimer’s more accessible and easier. These findings should be confirmed in larger and more diverse populations to determine how blood tests can best be integrated into routine clinical practice. 

For decades, diagnosing Alzheimer’s disease has often depended on recognizing symptoms after they appear. Research like this suggests a different future, one in which a simple blood test could help identify the disease much earlier. If that future becomes reality, it could give millions of people something they have never had before: more time to seek care, more time to make informed decisions, and more time for treatments that may slow the course of the disease.